(Q33684266)

28 July 2017

1 reference

title

Rosiglitazone (English)

1 reference

28 July 2017

Balfour JA

1

1 reference

28 July 2017

Plosker GL

series ordinal

2

1 reference

28 July 2017

publication date

1 June 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

57

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

921-30; discussion 931-2

1 reference

Novel euglycemic and hypolipidemic agents. 1

28 July 2017

cites work

1 reference

12 December 2020

Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates

1 reference

12 December 2020

The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat

1 reference

12 December 2020

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

1 reference

12 December 2020

The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats

1 reference

12 December 2020

Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.

1 reference

12 December 2020

Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice

1 reference

12 December 2020

Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes

1 reference

12 December 2020

Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells.

1 reference

12 December 2020

Mechanisms and clinical effects of thiazolidinediones

1 reference

12 December 2020

Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes.

1 reference

12 December 2020

Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention

1 reference

12 December 2020

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma

1 reference

12 December 2020

Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.

1 reference

12 December 2020

Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma

1 reference

12 December 2020

Troglitazone: a review of its use in the management of type 2 diabetes mellitus

1 reference

12 December 2020

Insulin resistance: current concepts

1 reference

12 December 2020

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study

1 reference

12 December 2020

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

12 December 2020

Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation

1 reference

12 December 2020

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats

1 reference

12 December 2020

Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y

1 reference

12 December 2020

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

12 December 2020

10.2165/00003495-199957060-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1046411976

0 references

1 reference